Clinical Trial Results: Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating allogeneic HB-adMSCs for early to moderate Parkinson's disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• HB-adMSCs (autologous adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Hope Biosciences Research Foundation | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-06-10